Invention Grant
- Patent Title: Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
-
Application No.: US16239869Application Date: 2019-01-04
-
Publication No.: US10682358B2Publication Date: 2020-06-16
- Inventor: Hariprasad Vankayalapati , Venkatakrishnareddy Yerramreddy
- Applicant: Arrien Pharmaceuticals LLC
- Applicant Address: US UT Salt Lake City
- Assignee: Arrien Pharmaceuticals LLC
- Current Assignee: Arrien Pharmaceuticals LLC
- Current Assignee Address: US UT Salt Lake City
- Agency: Foley & Lardner LLP
- Main IPC: C07C323/22
- IPC: C07C323/22 ; C07C211/14 ; C07D211/38 ; C07C211/58 ; C07D213/50 ; C07D231/12 ; C07D241/04 ; C07D277/42 ; C07D295/116 ; C07D295/135 ; C07D401/10 ; C07D413/10 ; C07D413/12 ; A61K31/5375 ; C07D211/14 ; C07D211/58 ; A61P17/06 ; A61P35/00 ; A61P37/00 ; A61K31/451 ; A61K31/4545 ; A61K31/495 ; A61K31/496 ; A61K31/5377 ; A61K31/122 ; A61K31/255 ; A61K31/44 ; A61K31/445

Abstract:
The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.
Public/Granted literature
Information query